Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR known ✓ | O43193 | 1/20 | 0.43 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.43 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.43 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.43 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.43 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.43 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.43 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.43 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.43 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.43 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.43 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.43 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.43 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.43 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.43 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.43 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6631974 | 1.00 | PARP14 (0.81) | PARP14BCHEHPGDSNPC1MLNR | |
| Fumaric Acid SCHEMBL7225813 | 0.97 | PARP14 (0.86) | PARP14BCHEHPGDSNPC1MLNR | |
| Fumaric Acid SCHEMBL7225810 | 0.97 | PARP14 (0.86) | PARP14BCHEHPGDSNPC1MLNR | |
| SCHEMBL6633296 | 0.93 | PARP14 (0.93) | PARP14BCHEHPGDSNPC1MLNR | |
| SCHEMBL7233408 | 0.87 | PARP14 (0.91) | PARP14BCHEHPGDSNPC1MLNR | |
| Fumaric Acid SCHEMBL7227141 | 0.85 | PARP14 (0.65) | PARP14BCHEHPGDSLMNADRD2 | |
| Fumaric Acid SCHEMBL7227144 | 0.85 | PARP14 (0.65) | PARP14BCHEHPGDSLMNADRD2 | |
| Fumaric Acid SCHEMBL7226160 | 0.85 | PARP14 (0.56) | PARP14LMNADRD2SLC6A2HRH2 | |
| Fumaric Acid SCHEMBL7226163 | 0.85 | PARP14 (0.56) | PARP14LMNADRD2SLC6A2HRH2 | |
| Fumaric Acid SCHEMBL7006837 | 0.84 | PARP14 (0.56) | PARP14BCHEHPGDSNPC1MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254189-A1 | Jnk inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1426050-A1 | JNK INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2004-06-09 | — | — | EP | disclosed |
| US-6610694-B1 | Suppressing histamine and/or eosinophil chemotaxis; treating allergic diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-26 | — | — | US | disclosed |
| EP-1120418-A1 | FUSED PYRIDAZINE COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2001-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254189-A1 | Jnk inhibitors | AR, MAPK1, MAPK3 | MLNR 2577/4885EGFR 322/4885ERBB2 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.